UBS Group’s Biolase BIOL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-5,615
Closed -$6.3K – 10278
2023
Q4
$6.3K Buy
+5,615
New +$8.02K ﹤0.01% 7712
2023
Q3
– Sell
-407
Closed -$2.89K – 10152
2023
Q2
$2.89K Buy
407
+371
+1,031% +$6.21K ﹤0.01% 7680
2023
Q1
$1.01K Buy
36
+19
+112% +$925 ﹤0.01% 8846
2022
Q4
$1.13K Sell
17
-39
-70% -$5.61K ﹤0.01% 9949
2022
Q3
$14K Buy
56
+51
+1,020% +$20.4K ﹤0.01% 7952
2022
Q2
$2K Buy
+5
New +$2.75K ﹤0.01% 9661
2022
Q1
– Hold
0
– – – 11119
2021
Q4
– Sell
-2
Closed -$2.52K – 10888
2021
Q3
$4K Sell
2
-5
-71% -$8.16K ﹤0.01% 8709
2021
Q2
$13K Hold
7
– – ﹤0.01% 7816
2021
Q1
$14K Buy
+7
New +$17.2K ﹤0.01% 7687
2020
Q4
– Sell
-18
Closed -$13.7K – 8872
2020
Q3
$13K Buy
18
+11
+157% +$10.3K ﹤0.01% 6659
2020
Q2
$8K Buy
7
+3
+75% +$3.42K ﹤0.01% 7163
2020
Q1
$4K Buy
+4
New +$6.22K ﹤0.01% 7425
2019
Q4
– Sell
-4
Closed -$6.15K – 8490
2019
Q3
$8K Hold
4
– – ﹤0.01% 7298
2019
Q2
$14K Hold
4
– – ﹤0.01% 6862
2019
Q1
$25K Buy
4
+2
+100% +$9.7K ﹤0.01% 6113
2018
Q4
$4K Hold
2
– – ﹤0.01% 7653
2018
Q3
$9K Sell
2
-2
-50% -$8K ﹤0.01% 7224
2018
Q2
$13K Hold
4
– – ﹤0.01% 7003
2018
Q1
$18K Buy
4
+2
+100% +$11.2K ﹤0.01% 6480
2017
Q4
$10K Sell
2
-2
-50% -$14.1K ﹤0.01% 7038
2017
Q3
$28K Buy
4
+2
+100% +$17.2K ﹤0.01% 6217
2017
Q2
$30K Buy
2
+1
+100% +$14.8K ﹤0.01% 6022
2017
Q1
$19K Sell
1
-1
-50% -$18.1K ﹤0.01% 6181
2016
Q4
$31K Buy
2
+1
+100% +$19.8K ﹤0.01% 6215
2016
Q3
$27K Hold
1
– – ﹤0.01% 6040
2016
Q2
$15K Hold
1
– – ﹤0.01% 6526
2016
Q1
$12K Hold
1
– – ﹤0.01% 6549
2015
Q4
$11K Buy
+1
New +$10.9K ﹤0.01% 7245
2015
Q3
– Hold
0
– – – 7972
2015
Q2
– Hold
0
– – – 7892
2015
Q1
– Hold
0
– – – 7931
2014
Q4
– Hold
0
– – – 8620

Other funds holding BIOL

UBS Group's BIOL Position: Q1 2024 in Review

UBS Group sold out of Biolase (BIOL) in Q1 2024, closing a stake of 5,615 shares — an estimated $6.3K sold.

UBS Group first reported a position in BIOL in Q4 2015 and held it in 28 quarters. The position peaked at $31K in Q4 2016. 18 funds tracked by Wall St. Rank hold BIOL as of Q1 2024.

  • UBS Group reported no remaining Biolase position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 5,615 Biolase shares in Q1 2024, an estimated $6.3K.
  • UBS Group first reported a position in Biolase in Q4 2015 and held it in 28 quarters.
  • UBS Group's Biolase position peaked at $31K in Q4 2016.
  • 18 funds tracked by Wall St. Rank held Biolase as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.